Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3
Submit an article Journal homepage
91
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Modeling cost–effectiveness of pharmaceuticals in Alzheimer's disease

Mark Oremus Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; McMaster Evidence-based Practice Centre, McMaster University, Hamilton, ON, Canada. [email protected]; McMaster Evidence-based Practice Centre, McMaster University, Hamilton, ON, Canada. [email protected]
&
Jean-Eric Tarride Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Programs for Assessment of Technologies in Health Research Institute, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Programs for Assessment of Technologies in Health Research Institute, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada
Pages 275-277 | Published online: 09 Jan 2014

References

  • Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation. BMC Neurol. 12, 2 (2012).
  • Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7(3), 137–152 (2011).
  • Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. 1, CD001190 (2006).
  • Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148(5), 379–397 (2008).
  • Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics 28(5), 411–427 (2010).
  • Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12(3), 189–198 (1975).
  • Mohs RC, Doody RS, Morris JC et al.; ‘312’ Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57(3), 481–488 (2001).
  • Winblad B, Engedal K, Soininen H et al.; Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57(3), 489–495 (2001).
  • Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57(4), 613–620 (2001).
  • Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer’s disease with donepezil over a 4-year period: lessons learned. Dement. Geriatr. Cogn. Disord. 25(3), 226–231 (2008).
  • Wolfson C, Wolfson DB, Asgharian M et al. A reevaluation of the duration of survival after the onset of dementia. N. Engl. J. Med. 344(15), 1111–1116 (2001).
  • Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48(Suppl. 6), S10–S16 (1997).
  • Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can. J. Psychiatry 56(10), 579–588 (2011).
  • Green C, Shearer J, Ritchie CW, Zajicek JP. Model-based economic evaluation in Alzheimer’s disease: a review of the methods available to model Alzheimer’s disease progression. Value Health 14(5), 621–630 (2011).
  • Cappell J, Herrmann N, Cornish S, Lanctôt KL. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs 24(11), 909–927 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.